Alle Storys
Folgen
Keine Story von BioLitec AG mehr verpassen.

BioLitec AG

biolitec AG achieved consolidated revenue of Euro 35.4 million for the fiscal year 2007/2008 -expectation of sales growth to resume in this fiscal year

Jena (euro adhoc) -

R&D expenditures with Euro 5.1 million remained at a high level – 
urology and aesthetic laser therapy remain growth markets – strongest
urology laser worldwide already in use in Germany
  ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
  the content of this announcement.
companies/finances/shares/stock market/Annual Report
Jena, September 30, 2008 - biolitec AG, Jena,
listed in the Prime Standard of the Frankfurt stock exchange (ISIN 
DE0005213409) posted a consolidated revenue of Euro 35.4 million for 
the fiscal year 2007/2008. Mainly contributing to this were the 
business segments urology laser, vein treatment and laser 
liposuction.
The revenue was 9% lower than in the prior year due to the 
unfavourable investment climate in the USA, its impact on the 
investment cycle and the unfavourable dollar exchange rate. In the 
USA biolitec AG is market leader in the sector of ambulant therapy of
the benign prostate hyperplasia (BPH). More than 600 US urologists 
already have applied LIFE™ laser therapy, about 200 as in-office 
treatment. At the 2008 American Urological Association´s (AUA) 
National Scientific Meeting in Orlando/Florida US urologists were 
keen on the gentle in-office treatment with biolitec´s laser Evolve™ 
150 and the short treatment time.
R&D expenditures for the fiscal year 2007/2008 of Euro 5.1 million 
(14% of sales) remained at a high level to ensure the groups long 
term growth and profitability. Net income amounted to about Euro 2 
million despite the continuous high R&D investments as well as the 
decline in sales. The gross profit amounted to about Euro 24 million 
and EBIT amounted to Euro 1.4 million.
For example biolitec has just revolutionized endovenous laser 
treatment for varicose veins by the application of the new, 
innovative laser fiber ELVeS® RADIAL, which emits the light radially.
The revenue posted by the laser segment of Euro 12.1 million was 
lower than in the prior year mainly due to the market decline in the 
USA. The fiber optics and laser probes segment contributed to about 
Euro 22 million to the group´s total revenue. Mainstays of sales are 
the LIFE™ BPH laser treatment and the Endoluminal Laser Treatment of 
Veins (ELVeS™).
The urology laser Evolve™ 150 is rising further in the estimation of 
physicians and the number of LIFE™ laser treatment centres is 
increasing continuously. In Germany the outpatient treatment of BPH 
with the Evolve™ laser is gaining ground. The biolitec AG has 
recently introduced the first 300 watt urology laser to the German 
market.
biolitec´s major revenues were again generated in Europe and North 
America. With Euro 14.7 million, sales in North America were 22% 
lower than previous year´s sales contributing 42% of total sales. 
European sales amounted to Euro 17.9 million (previous year 17.8%).
Dr. Wolfgang Neuberger, CEO of biolitec AG: "We proceed on the 
assumption that the demand on gentle urology therapies as well as 
treatments in the field of aesthetics will further increase and the 
market caution will decrease. Due to our excellent market position in
Europe and North America we expect an increase in turnover and profit
in the current fiscal year even driven by the expenditures of 
transacted research and development."
About biolitec biolitec is the only supplier for photodynamic therapy
worldwide that offers all relevant core competencies - 
photosensitizers, lasers and optical fibers. Besides minimal invasive
laser treatments and the oncology business biolitec has successfully 
developed competencies in the field of aesthetics. biolitec is listed
in the Prime Standard under ISIN DE0005213409. For more information: 
www.biolitec.com.
end of announcement                               euro adhoc

Further inquiry note:

Press contact
Jörn Gleisner
Telefon : +49 (0) 69 / 959083-20
Telefax : +49 (0) 69 / 959083-99
E-Mail: joern.gleisner@biolitec.com

Branche: Pharmaceuticals
ISIN: DE0005213409
WKN: 521340
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse München / free trade

Weitere Storys: BioLitec AG
Weitere Storys: BioLitec AG